Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published September 15, 2014 | Published + Supplemental Material
Journal Article Open

Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity

Abstract

The majority of oligodendrogliomas (ODGs) exhibit combined losses of chromosomes 1p and 19q and mutations of isocitrate dehydrogenase (IDH1-R132H or IDH2-R172K). Approximately 70% of ODGs with 1p19q co-deletions harbor somatic mutations in the Capicua Transcriptional Repressor (CIC) gene on chromosome 19q13.2. Here we show that endogenous long (CIC-L) and short (CIC-S) CIC proteins are predominantly localized to the nucleus or cytoplasm, respectively. Cytoplasmic CIC-S is found in close proximity to the mitochondria. To study wild type and mutant CIC function and motivated by the paucity of 1p19q co-deleted ODG lines, we created HEK293 and HOG stable cell lines ectopically co-expressing CIC and IDH1. Non-mutant lines displayed increased clonogenicity, but cells co-expressing the mutant IDH1-R132H with either CIC-S-R201W or -R1515H showed reduced clonogenicity in an additive manner, demonstrating cooperative effects in our assays. Expression of mutant CIC-R1515H increased cellular 2-Hydroxyglutarate (2HG) levels compared to wild type CIC in IDH1-R132H background. Levels of phosphorylated ATP-citrate Lyase (ACLY) were lower in cell lines expressing mutant CIC-S proteins compared to cells expressing wild type CIC-S, supporting a cytosolic citrate metabolism-related mechanism of reduced clonogenicity in our in vitro model systems. ACLY or phospho-ACLY were similarly reduced in CIC-mutant 1p19q co-deleted oligodendroglioma patient samples.

Additional Information

© 2014 Impact Journals, LLC. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Received: April 01, 2014 Accepted: August 26, 2014 Published: August 27, 2014. We thank the DNA sequencing, library construction, and biospecimen cores at the BC Cancer Agency Genome Sciences Centre for technical support. We thank Robyn Roscoe for expert Project Management support. The authors thank Chandra Lebovitz and Dr. Jill Mwenifumbo for helpful edits and comments on the manuscript. We thank Drs. Carol MacKintosh (University of Dundee, Scotland, UK) and Huda Y. Zoghbi (Howard Hughes Medical Institute, Houston, Texas) for providing us with CIC constructs. We thank Dr. G. Dawson (The University of Chicago, Illinois, USA) for providing us the HOG glioma cell line. We thank Drs. Andreas von Deimling and Joerg Balss (DKFZ - German Cancer Research Center, Heidelberg, Germany) for providing us with HGDH enzyme for 2HG enzymatic assays. MAM acknowledges the support of the Canada Research Chairs program and the BC Cancer Foundation, and is especially grateful to Ms. Donna Anderson for her generosity in supporting this project. SMG gratefully acknowledges support from CIHR MOP-78882 and a CIHR New Investigator award. GBM acknowledges support from the BC Cancer Foundation. JGC is supported by the Alberta Cancer Foundation, the Terry Fox Research Institute and Foundation, and the generosity of the family of Clark H. Smith. SY acknowledges generous support from BrainCareBC and a VCHRI Mentored Clinician Scientist Award.

Attached Files

Published - 2401-27606-3-PB.pdf

Supplemental Material - 2401-27616-1-SP.pdf

Files

2401-27606-3-PB.pdf
Files (4.5 MB)
Name Size Download all
md5:a7643383239e57e7f646fc9eccf6c5a1
3.7 MB Preview Download
md5:09a6291f72cd515e08d39414b736ddcc
847.2 kB Preview Download

Additional details

Created:
August 22, 2023
Modified:
October 17, 2023